<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although a number of reports have suggested clinical efficacy of low-dose Ara-C (LoDAC) in the treatment of <z:hpo ids='HP_0011009'>acute</z:hpo> non-lymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (ANLL) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), this therapy remains controversial </plain></SENT>
<SENT sid="1" pm="."><plain>Clinical trials presently are being conducted to determine the efficacy of LoDAC in these <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Patient education related to self-administration of the agent and monitoring of potential toxicities are primary components of nursing management </plain></SENT>
<SENT sid="3" pm="."><plain>It is likely that nurses in <z:hpo ids='HP_0011009'>acute</z:hpo> care, ambulatory, and community settings will be involved in the management of patients receiving this therapy </plain></SENT>
</text></document>